Shanghai Labway Clinical Laboratory Co

Shanghai Labway Clinical Laboratory Co FCF Yield

The Free Cash Flow Yield of Shanghai Labway Clinical Laboratory Co (301060.SZ) as of Nov 3, 2026 is 4.69 %. In the previous year, Free Cash Flow Yield was 3.12 % — a change of 50.58% (higher).

FCF Yield

4.69 %

YoY

50.58%

Last updated:

Free Cash Flow Yield of Shanghai Labway Clinical Laboratory Co is 2025 4.69 % . Free Cash Flow Yield of Shanghai Labway Clinical Laboratory Co was 2024 3.12 % . It decreases by 50.58% higher compared to the previous year.

The Shanghai Labway Clinical Laboratory Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
2.49 CNY
Jan 1, 2019
0.69 CNY
Jan 1, 2020
2.75 CNY
Jan 1, 2021
2.33 CNY
Jan 1, 2022
-3.26 CNY
Jan 1, 2023
3.30 CNY
Jan 1, 2024
3.12 CNY
Jan 1, 2025
4.69 CNY
The Shanghai Labway Clinical Laboratory Co FCF Yield history
YEARFCF YieldYoY
4.69 %+50.58%
3.12 %-5.68%
3.30 %-201.50%
-3.26 %-239.46%
2.33 %-15.16%
2.75 %+296.69%
0.69 %-72.11%
2.49 %-149.29%
-5.05 %+197.11%
-1.70 %-304.32%
0.83 %-138.14%
-2.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Labway Clinical Laboratory Co Stock analysis

What does Shanghai Labway Clinical Laboratory Co do? Shanghai Labway Clinical Laboratory Co., Ltd. generates revenue through medical and pathological examination services, including pathological diagnosis, molecular examination, biochemical examination, immune examination, microbial examination, clinical basic examination, and physical and chemical examination. The company also sells in vitro diagnostic instruments, reagents, and related accessories and consumables. Its primary customers are healthcare providers and medical institutions requiring diagnostic services and diagnostic products. The business segments are medical testing services and in vitro diagnostic product sales. The company's medical testing services cater to hospitals and clinics seeking comprehensive diagnostic solutions, while the in vitro diagnostic product sales target healthcare facilities needing equipment and supplies for laboratory operations. These services and products are provided to clients across China, focusing on the healthcare sector's demand for accurate and timely diagnostic capabilities. Shanghai Labway's revenue streams are derived from both service fees for examinations and sales of diagnostic instruments and reagents. The company's offerings align with the growing need for advanced medical diagnostics in China's expanding healthcare market, serving a broad client base within the medical industry. Shanghai Labway Clinical Laboratory Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Labway Clinical Laboratory Co stock

Free Cash Flow Yield of Shanghai Labway Clinical Laboratory Co is 4.69 % in 2025.

Free Cash Flow Yield of Shanghai Labway Clinical Laboratory Co changed from 3.12 % to 4.69 %, representing a 50.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Shanghai Labway Clinical Laboratory Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Shanghai Labway Clinical Laboratory Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Shanghai Labway Clinical Laboratory Co

All Key Metrics — Shanghai Labway Clinical Laboratory Co